Search Clinical Trials in the European Union

6-12 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
361-380 of 397 trials

Chronic Obstructive Pulmonary Disease: AZD6793 Tablets

We are investigating whether AZD6793 can help reduce flare-ups in adults with moderate to very severe COPD. The study will also look at its effects on lung function and overall health.

Chronic Obstructive Pulmonary Disease (COPD)6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemotePulmonology

Haemophilia A: Inno8 Medication Study

We are researching how different doses of the medication Inno8 work in people with haemophilia A. This study aims to understand its effects on the body.

Haemophilia A6-12 monthsSafety phase (I)Hematology

Plaque Psoriasis and Eczema: RLS-1496 Cream

We are testing a new topical cream for patients with plaque psoriasis or eczema. The goal is to see how safe it is and how well it works compared to existing treatments.

Atopic DermatitisPsoriasis6-12 monthsSafety phase (I)AllergologyDermatology

PF-07940369: Tolerance Study in Healthy Adults

We are investigating how well different amounts of the medicine PF-07940369 are tolerated by healthy adults. This study will help us understand its effects in the body.

Clonal Hematopoiesis6-12 monthsSafety phase (I)Hematology

GSK5764227 for Advanced Gastrointestinal Tumors

We are studying a new treatment for patients with advanced unresectable or metastatic gastrointestinal tumors that have been previously treated. The trial aims to evaluate how well this treatment works and its safety.

Gastrointestinal Neoplasms6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboCost ReimbursementPartially RemoteGastroenterologyOncology

Kidney Health: BIA 28-6156 Study

We are evaluating a new medication for people with varying degrees of kidney impairment. The study focuses on its safety and how the body processes it.

Parkinson's Disease6-12 monthsSafety phase (I)NephrologyNeurology

Tonsillectomy Pain Relief: Ropivacaine vs. Lidocaine

We are comparing two local anesthetics to see which one better reduces pain after tonsillectomy. This study aims to find the most effective option for managing postoperative discomfort.

Chronic Tonsillitis6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesOtolaryngology

Botulinum Toxin Treatment: Patient Satisfaction Study

We are examining how satisfied patients are with split doses of botulinum toxin compared to a control group. The study also looks at the safety of this treatment over time.

Frown Lines6-12 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsInvestigational MedicinesDermatology

Pomalidomide for Chronic Hepatitis B Infection

We are studying the safety of pomalidomide in people with chronic hepatitis B. The trial also looks at how this medication may improve immune responses and liver health.

Hepatitis B Virus Infection6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHepatologyInfectious Diseases

HIV Treatment: MK-4646 Study

We are testing a new medication, MK-4646, for people living with HIV. The study aims to see how well it works in managing the virus compared to current treatments.

HIV Infection6-12 monthsSafety phase (I)Infectious Diseases

Birth Control Study: Levonorgestrel Tablet

We are investigating whether the Levonorgestrel tablet can still prevent ovulation despite planned delays in taking the pill. This study is for individuals interested in understanding the reliability of this contraceptive method.

Ovulation Inhibition6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and Obstetrics

Axial Spondyloarthritis: EAST-1 Trial

We are investigating a new treatment that targets ERAP inhibition for individuals with axial spondyloarthritis. The goal is to see if this approach improves symptoms compared to standard care.

Axial Spondyloarthritis6-12 monthsSafety phase (I)Rheumatology

Olmsted Syndrome: KM-023 Treatment Study

We are testing a new treatment called KM-023 in healthy volunteers and patients with Olmsted syndrome. The goal is to learn about its safety and how it may help those affected by this condition.

Olmsted Syndrome6-12 monthsSafety phase (I)Dermatology

Quabodepistat: Understanding Liver Function Impact

We are studying how Quabodepistat is processed in adults with reduced liver function versus those with normal liver function. This research may help improve treatment safety and effectiveness for individuals with liver conditions.

Tuberculosis6-12 monthsSafety phase (I)HepatologyInfectious Diseases

Migraine Study: Effects of Cilostazol

We are investigating how cilostazol affects migraine headaches in men and women without aura. The study looks at potential differences in response based on sex.

Migraine6-12 monthsSafety phase (I)Efficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteNeurology

ARGX-121: Safety Study in Healthy Adults

We are assessing the safety of the new treatment ARGX-121 in healthy adult participants. This study aims to ensure the treatment is safe for future use.

Healthy Volunteers6-12 monthsSafety phase (I)AllergologyInfectious Diseases

TAR-0520 Gel for Preventing Nerve Damage in Breast Cancer Patients

We are studying whether TAR-0520 Gel can safely prevent nerve damage and nail changes in patients receiving taxane chemotherapy for breast cancer.

Chemotherapy-Induced Peripheral Neuropathy6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesInternal MedicineNeurologyOncology

NTX-1955: Effects on Brain Function

We are examining how the oral medication NTX-1955 affects the brain in healthy adults. This study aims to gather insights that could inform future treatments.

Generalized Anxiety Disorder6-12 monthsSafety phase (I)Psychiatry

Testing CLE-905-AG for Safety and Tolerability

We are studying a new medication to see how safe it is and how the body handles it in healthy individuals. This trial will also explore its effects when combined with another drug.

Schizophrenia6-12 monthsSafety phase (I)Psychiatry

LY3537031 for Liver Function Study

We are investigating how LY3537031 affects people with normal liver function and those with mild to severe liver impairment. This study aims to learn more about its safety and effectiveness in different liver health conditions.

Healthy Participants6-12 monthsSafety phase (I)HepatologyInternal Medicine